

# TRANSCHEM LIMITED

05 February 2022

To,

Corporate Relation Department  
BSE Limited,  
P. J. Towers, 1<sup>st</sup> Floor,  
Dalal Street, New Trading Ring,  
Rotunda Building, Fort,  
**MUMBAI – 400 001.**

**SUB: Unaudited Financial Results for the Quarter/Nine months ended December  
31, 2021**

**REF: COMPANY CODE NO. 500422.**

Dear Sir,

Pursuant to regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 we are submitting herewith statement of Unaudited Financial Results of the company for the quarter and nine month ended 31 December 2021 along with copy of Limited Review Report of the Auditors on the same in the prescribed format.

The results are being reviewed by the Audit Committee and taken on record by the Board of Directors in their respective meetings held on 05 February 2022.

These results are also being placed at the web-site of Company ([www.transchem.net](http://www.transchem.net)).

Please take the same on record.

Thanking you,

Yours faithfully,

For **TRANSCHEM LIMITED**

(Neeraja Karandikar)  
Company Secretary (ACS 10130)

Encl: As above.

CIN : L24100MH1976PLC019327

**Regd. Office** : 304, Ganatra Estate, Pokhran Road No. 1, Khopat, Thane (W) 400 601.


Tel.: 022-2547 7077 Telefax : 022-2547 8601 E-mail : [secretary@transchem.net](mailto:secretary@transchem.net) Website : [www.transchem.net](http://www.transchem.net)

**Limited Review Report on Unaudited Quarterly Standalone Financial Results and Unaudited Year to Date Financial Results of Transchem Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, as amended**

To The Board of Directors of  
Transchem Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of Transchem Limited ("the Company") for the quarter and nine months ended December 31<sup>st</sup>, 2021 (the "Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Maheshwari & Co.  
Chartered Accountants  
FRN: 105834W

  
Pawan Gattani  
Partner  
Membership No. 144734



UDIN: 22144734AANRDO8306  
Place: Mumbai  
Date: February 05, 2022





# TRANSCHEM LIMITED

CIN : L24100MH1976PLC019327  
Email : secretary@transchem.net  
Website : www.transchem.net

## Statement of Unaudited Financial Results for the Quarter and Nine Months Ended 31 December 2021

| Sr. No. | Particulars   | (Rupees in Lakhs, unless otherwise stated) |                            |                            |                            |                            |                          |
|---------|---|--|----------------------------|----------------------------|----------------------------|----------------------------|--------------------------|
|         |   | Quarter Ended                              |                            |                            | Nine Months Ended          |                            | Year Ended               |
|         |   | 31 Dec 2021<br>(Unaudited)                 | 30 Sep 2021<br>(Unaudited) | 31 Dec 2020<br>(Unaudited) | 31 Dec 2021<br>(Unaudited) | 31 Dec 2020<br>(Unaudited) | 31 Mar 2021<br>(Audited) |
| 1       | <b>Income</b>   |  |                            |                            |                            |                            |                          |
|         | a) Income from operations   | -  | -                          | -                          | -                          | -                          | -                        |
|         | b) Other income   | 143.03                                     | 139.29                     | 126.52                     | 426.52                     | 309.13                     | 437.33                   |
|         | c) Gain on sale of property, plant and equipment (refer note 4)     | -  | -                          | -                          | -                          | 2,245.90                   | 2,245.90                 |
|         | <b>Total Income</b>   | <b>143.03</b>                              | <b>139.29</b>              | <b>126.52</b>              | <b>426.52</b>              | <b>2,555.03</b>            | <b>2,683.23</b>          |
| 2       | <b>Expenses</b>   |  |                            |                            |                            |                            |                          |
|         | a) Cost of materials consumed                                       | -  | -                          | -                          | -                          | -                          | -                        |
|         | b) Employee benefit expenses  | 21.45                                      | 20.38                      | 20.01                      | 61.92                      | 53.98                      | 81.45                    |
|         | c) Depreciation and amortisation expenses                           | 0.20                                       | 0.19                       | 0.17                       | 0.59                       | 12.23                      | 12.43                    |
|         | d) Finance cost   | -  | 0.01                       | -                          | 0.01                       | 0.10                       | 0.13                     |
|         | e) Other expenses   | 15.63                                      | 28.87                      | 15.54                      | 55.97                      | 89.97                      | 112.26                   |
|         | <b>Total Expenses</b>   | <b>37.28</b>                               | <b>49.45</b>               | <b>35.72</b>               | <b>118.49</b>              | <b>156.28</b>              | <b>206.27</b>            |
| 3       | <b>Profit / (Loss) before exceptional items (1-2)</b>               | <b>105.75</b>                              | <b>89.84</b>               | <b>90.80</b>               | <b>308.03</b>              | <b>2,398.75</b>            | <b>2,476.96</b>          |
| 4       | Exceptional Items   | -  | -                          | -                          | -                          | -                          | -                        |
| 5       | <b>Profit / (Loss) before tax (3-4)</b>                             | <b>105.75</b>                              | <b>89.84</b>               | <b>90.80</b>               | <b>308.03</b>              | <b>2,398.75</b>            | <b>2,476.96</b>          |
| 6       | Tax expense   | 26.88                                      | 23.06                      | 18.49                      | 78.35                      | 41.69                      | 61.95                    |
| 7       | <b>Net Profit / (Loss) for the period/year (5-6)</b>                | <b>78.87</b>                               | <b>66.78</b>               | <b>72.31</b>               | <b>229.68</b>              | <b>2,357.06</b>            | <b>2,415.01</b>          |
| 8       | Other comprehensive income (OCI) (Net of tax)                       |  |                            |                            |                            |                            |                          |
|         | <u>Items that will not be reclassified to profit or loss</u>        |  |                            |                            |                            |                            |                          |
|         | - Re-measurement gain/ (losses) on defined benefit plans            | 0.20                                       | 0.90                       | (0.05)                     | 0.62                       | (0.15)                     | (2.08)                   |
|         | - Net gain / (loss) on investments designated at FVTOCI             | 164.57                                     | (160.17)                   | 86.54                      | 5.27                       | 91.96                      | 204.71                   |
| 9       | <b>Total comprehensive income for the period (net of tax) (7+8)</b> | <b>243.64</b>                              | <b>(92.49)</b>             | <b>158.80</b>              | <b>235.57</b>              | <b>2,448.87</b>            | <b>2,617.64</b>          |
| 10      | Paid-up Equity Share Capital<br>(Face value ₹10 per share)          | 1,224.00                                   | 1,224.00                   | 1,224.00                   | 1,224.00                   | 1,224.00                   | 1,224.00                 |
| 11      | Other Equity  | NA   | NA                         | NA                         | NA                         | NA                         | 5,070.15                 |
| 12      | Earning per share (EPS) (in ₹) (not annualised)                     |  |                            |                            |                            |                            |                          |
|         | i). Basic EPS   | 0.64                                       | 0.55                       | 0.59                       | 1.88                       | 19.26                      | 19.73                    |
|         | ii). Diluted EPS  | 0.64                                       | 0.55                       | 0.59                       | 1.88                       | 19.26                      | 19.73                    |

### Notes:

- The financial results of Transchem Limited ('the Company') for the quarter and nine months ended 31 December 2021 have been reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors in their meeting held on 05 February 2022 and have been subjected to Limited Review by the Statutory Auditors of the Company. There are no qualifications in the limited review report issued for the quarter and nine months ended 31 December 2021.
- During the nine months ended 31 December 2021 and financial year 2020-21, the Company does not have revenue from operations and hence for the purpose of disclosure of segment information, the Company does not have a business segment. Further, the Company operates in India and accordingly no disclosures are required under secondary segment reporting.
- The Unaudited Financial Results of the Company have been prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind-AS") as prescribed under section 133 of the Companies Act 2013, as amended, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended and SEBI Circular No.CIR/CFD/CMD 1/44/2019 dated March 29, 2019.
- During the quarter ended 30 June 2020, the Company had sold out its undertaking known as "Mushroom Plant" consisting of pieces and parcels of lands or ground bearing Gat nos. 379, 382, 380, 381, 384, 416 (part), 433, 434, 435, 438, 436 (part), and 383 of Village Bebadohal and Gat no. 579 (part) of Village Urse, Taluka Maval, District Pune 410 506, together with its land, structures, machinery and fixtures therein and accordingly the Company had recognised the gain on sale of the said area of Mushroom Plant during the said quarter.
- The previous periods numbers have been regrouped/ rearranged wherever necessary to confirm the current period presentation.

For Transchem Limited

*Ms. Ranavre*



Mahesh Suresh Ranavre

Director

DIN:08296631

Place: Thane

Date: 5 February 2022



Regd. Office : 304, Ganatra Estate, Pokhran Road No. 1, Khopat, Thane (W) 400 601  
Tel. : 022-2547 7077 Telefax : 022-2547 8601